BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against Altimmune, Inc. (NASDAQ:ALT) and certain of its executives. Investors who have lost money in their Altimmune, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/alt.
What is this all about?
Altimmune stock fell on February 13, 2024, following publication of a report noting that Altimmune's GLP-1 drug had low tolerability and was unlikely to generate the partnership opportunities the company needed to succeed. Then, on April 29, market analyst Guggenheim noted that a partership looked "increasingly unlikely," again causing the stock to fall. The lawsuit alleges that the company overstated its prospects for finding a ...